Liver-Derived Stem Cells Outperform Bone Marrow and Fat Cells at Reversing Fibrosis in Rats

Liver fibrosis is the excessive buildup of scar tissue after chronic liver injury from viral hepatitis, alcohol, or fatty liver disease. Left unchecked, it can progress to cirrhosis, liver failure and hepatocellular carcinoma, and transplantation is often the only option for advanced disease. Mesenchymal stem cells (MSCs) are being explored as a regenerative alternative, but it is unclear which tissue source works best.

This study compared MSCs from three sources: bone marrow (BM-MSCs), adipose tissue (AD-MSCs) and liver (L-MSCs). Fifty male Wistar rats were split into five groups of ten: healthy control, thioacetamide (TAA) only, and TAA plus one of the three cell types. TAA, a hepatotoxin, was injected at 100 mg/kg twice weekly for nine weeks. Treated groups received a single tail-vein dose of 3 × 10^6 cells at week 5, partway through the injury period. The researchers measured serum liver function (ALT, AST, total bilirubin, albumin) and oxidative stress markers (GSH, SOD, CAT, MDA, nitric oxide). They also measured fibrosis markers (hydroxyproline, collagen type 1 by ELISA), alpha-smooth muscle actin (ASMA) gene expression by PCR, and the percentage of fibrotic area on histology.

All three MSC types improved outcomes compared with untreated TAA rats. ALT, AST and bilirubin fell significantly in every cell-treated group, and the L-MSC group showed the largest decrease. Albumin rose notably with L-MSCs. L-MSC treatment also produced clear increases in GSH, SOD and CAT and decreases in MDA and nitric oxide, indicating better antioxidant status. Hydroxyproline and collagen type 1 declined, ASMA expression was significantly downregulated, and histological fibrosis was lowest in the L-MSC group. The authors conclude that MSCs from different sources ameliorate fibrosis, with liver-derived cells giving the best results.

The results suggest that the tissue of origin may shape how well MSCs repair the liver, possibly because liver-derived cells are better adapted to the hepatic environment. They also reinforce the case for MSC therapy as an anti-fibrotic strategy. However, the supplied text gave no exact effect sizes, p-values or mechanistic data, so the size of the differences between cell types is not clear.

Several caveats apply. This is a short-term rodent study with a single toxin model, one cell dose and one timing. No power calculation was performed. Cells were taken from rats rather than humans, and the study did not track whether cells engrafted in the liver or acted through secreted factors. The study did not test durability of benefit, safety, or whether fibrosis regressed rather than just stopped progressing. Human liver-derived MSCs are also far harder to source than bone marrow or fat cells, which limits practical translation.